18 April 2019 | NewsUpdated information on measles vaccination in AustraliaRead the full article
From January 2018 a new HPV vaccine, Gardasil9®, is being funded under the National Immunisation Program. AusVaxSafety is monitoring the safety of HPV vaccine in 11- to 14-year olds. Injection site reactions, including pain, are known to occur following administration of HPV vaccines, and the current reported event rates are consistent with what are expected according to the existing data.
From 1 July 2018, maternal pertussis vaccine is being funded for pregnant women under the National Immunisation Program. AusVaxSafety is monitoring the safety of maternal pertussis vaccines in the days following immunisation. The current reported event rates are consistent with existing data on the safety of maternal pertussis vaccines.
Injection site reactions are known to occur following administration of acellular pertussis vaccines. The current reported event rates are consistent with existing data on pertussis vaccines.
In the context of no safety signals identified during two years of surveillance in over 18,000 participants, AusVaxSafety concluded active surveillance of zoster vaccine safety in November 2018. It is important to re-emphasise that zoster vaccine should not be given to immunocompromised individuals. For more information please refer to the Therapeutic Goods Administration (TGA) website.
Surveillance of 2019 influenza vaccine safety commenced from 1 April 2019. For children under 5 years of age, 2018 results are presented until adequate numbers of responses are received. The current reported event rates are consistent with existing data on influenza vaccines.
NCIRS, Kids Research, Sydney Children’s Hospitals Network, Cnr Hawkesbury Rd & Hainsworth St, Westmead Locked Bag 4001, Westmead NSW 2145 Tel (612) 9845 1433 | Fax (612) 9845 1418 | ABN 53 188 579 090
We acknowledge that the National Centre for Immunisation Research & Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.
Our website meets the criteria for credibility and content as defined by the Global Advisory Committee on Vaccine Safety.